SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 9th, 2024 • Imunon, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 9th, 2024 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of [•], 2024, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
SERIES B WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC.Warrant Agreement • February 9th, 2024 • Imunon, Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 9th, 2024 Company IndustryTHIS SERIES B WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Original Issuance Date (the “Initial Exercise Date”) and on or prior to 5:00 pm (New York City time) on [*] __, 2025[1] (the “Termination Date”) but not thereafter, to subscribe for and purchase from IMUNON, INC., a Delaware corporation (the “Company”), up to ______ shares of Common Stock, par value $0.01 per share (the “Common Stock”), of the Company (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).